Oncocyte Corporation - Common Stock (OCX)

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.

Penny stocks are a risky business but following the insiders to your next trade can alleviate some of the risks; these are the three hottest insider buys.

Interventional study compares VitaGraft to current transplant rejection monitoring protocols

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023

First digital-droplet PCR assay to receive coverage

Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023

IRVINE, CA / ACCESSWIRE / August 9, 2023 / Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed.

Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET

Echelon Diagnostics, Inc., a leading provider of genomic healthcare AI imaging and big data solutions, today announced a strategic collaboration with Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum. The two companies will work together to develop analytical software that can scale to support the commercial expansion of Oncocyte’s tests and solutions that may help diagnosis and treatment of cancer, leading to improved patient outcomes and reducing the overall cost of care.